The synthesis, characterization and biological assays of two new rhodium carboxylate sugar derivatives and respective cyclosphosphamide adducts are described. The compounds, characterized by q3C and IH NMR, infrared and UV-visible spectra, presented high water solubility and hydration grades were confirmed given the concordance between thermal and CHN analyses. The adducts were active in vitro against K-562 cells.
INTRODUCTION
Ever since Rosenberg et al. introduced cisplatin in turnout disease therapeutics, researchers became increasingly interested in this field, giving rise to a number of published findings on platinum group metal complexes. In 1972, Bear and co-workers reported that rhodium (II) carboxylates present anti-tumoural activity2. Albeit the promising start, interest in this class of compounds as anti-tumoural agents has somewhat decreased mostly in view of significant toxicity levels. Currently, a number of papers have been issued in an attempt to identify less toxic derivatives 3-8. One of the best means of obtaining chemotherapeutical metal complexes is to synthesize adducts using ligand molecules that are, by their very nature, biologically active. To this effect, cyclophosphamide (CP) (Fig.l) has been used to obtain adducts with rhodium(II) carboxylates. The compounds were submitted to biological assays and results indicated that the complexes were not active 9. This might be partially due to the fact that these present somewhat low water solubility levels. With views to obtaining compounds that present the appropriate partition coefficient for biological assays, two new rhodium(II) derivatives, Rhz(GU)4 and Rh2(KG)4, rhodium glucuronate and rhodium keto-gluconate (Fig.l) H, 3C and 31p NMR shift data are pictured in Table 4 , while 
